Table 2:
Registry website reports 2025.
| Age (years) | Gender | Comorbidities | Reason for the intravitreal drug | Drug frequency | Drug | Effects reported for drugs |
|---|---|---|---|---|---|---|
| 30 | Male | CKD, diabetes, HTN | DME | Every 2 weeks | Bevacizumab | sCr 1.4→2→3 since starting avastin 2022→2024. UPCR 6 g. MACR 1.3 g→4 g 2022→2024. HTN worsening. +DR DM/DN |
| 36 | Male | CKD, diabetes, HTN | DME | Monthly | Bevacizumab | sCr 1.3→1.5→2.5 over last 2 years. Proteinuria 1→2.7→3.5 g over last 2 years |
| 65 | Female | CKD, diabetes, HTN | DME | Every 2 weeks | Bevacizumab | Avastin likely drug. sCr increase 0.7 to 1.2 |
| 62 | Male | CKD, diabetes, dialysis, heart attack, HTN | Every 3 months new VEGFi (q 3 months—faricimab) | Bi-monthly or less often | Other | Proteinuria in allograft of transplant patient 1→ 4.3 g over last period post 1st injection. Allograft biopsy planned. 1.3 sCr→1.5 mg/dL |
| 61 | Male | CKD, diabetes, heart attack, HTN | DME | Monthly | Bevacizumab | sCr worsening from 1.9–2 up to 3.7 mg/dL and rua showing 500+ proteinuria (nephrotic range); no MACR or UPCR |
| 53 | Female | CKD | DR | Monthly | Bevacizumab | From time of initiation sCr increased to 7–10 g proteinuria. Rapid progression of CKD |
| 47 | Female | CKD, diabetes, heart attack, HTN | Diabetes | Monthly | Ranibizumab | After intravitreal ranibizumab injection, existing proteinuria raised to a nephrotic level in multiple occurrences. Renal biopsy performed when proteinuria was 14 g/day and serum albumin 2.9 g/dL. It showed DN and acute TIN (eosinophil dominant inflammation and tubulitis). The patient has Class 3 obesity, as well |
| 79 | Male | CKD, diabetes | AMD | Monthly | Aflibercept | New-onset proteinuria from 1+ to 3+. 140 mg/day uACR to 1 g/day |
| 47 | Male | Anemia, CKD, diabetes, HTN | Diabetic retinopathy got 6 weeks before injury per pt (last known well kidney function 1.5→3.6) | Every 2 weeks | Bevacizumab | Nephrotic-range proteinuria 10 g of protein. Biopsy suggested |
| 43 | Female | CKD, HTN | VEGFi for DME | Monthly | Bevacizumab | 200 mg/g of proteinuria (albuminuria) initially in 2017 when started IVEGF→increase to 10 g/day of proteinuria |
| 67 | Female | CKD, diabetes, heart attack, HTN | DME | Monthly | Bevacizumab | Patient with worsening renal function (accelerated DM and DN) |
| 75 | Male | HTN | AMD | bi-monthly or less often | Aflibercept | Worsening HTN, no proteinuria or hematuria |
| 74 | Male | CKD, HTN | Macular degeneration | Monthly | Aflibercept | No proteinuria noted, but accelerated HTN, with swings. HTN diagnosis seemed to start around time of starting IVEGFi |
| 53 | Male | CKD, diabetes, HTN | DR | Bi-monthly or less often | Bevacizumab | Nephrotic-range proteinuria |
| 58 | Male | CKD | DM | Bi-monthly or less often | Bevacizumab | MACR went from 1.3→5 g in span of 5 months. UPCR 4.7 g |
| 47 | Female | HTN | Proliferative diabetic retinopathy | Monthly | Other | Worsening HTN and worsening proteinuria |
sCr, serum creatinine; MACR, microalbumin creatinine ratio; DN, diabetic nephropathy; rua, random urine analysis; TIN, tubulointerstitial nephritis; uACR, urine albumin creatinine ratio.